Company Profile

Takeda Pharmaceutical Company Limited

4502 · TSE
Other listingsTAK · US
Industry
Pharmaceuticals
Exchange
TSE
Price at Publication
¥5,968
Sep 24, 2026 close
Fair Buy
≤ ¥3,700
Margin-of-safety entry
Baillie Growth Score
40/100
Weak
Intrinsic Value · Three-Tier Range Price at publication ¥5,968 · Within the fair intrinsic-value range

Composite valuation range · conservative ¥3,500–¥3,700 / fair ¥5,500–¥7,400 / optimistic ¥8,850–¥9,600. At the publication price of ¥5,968 (Sep 24, 2026), Within the fair intrinsic-value range.

About the company

Company overview coming soon.

Background

History

Coming soonThis section is being filled in — check back soon.

Industry position

Coming soonThis section is being filled in — check back soon.

Research on this stock
40/100 Hold Takeda: Q1 Revenue Rose 10.2% in Yen but Core Revenue Fell 0.5% at CER, U.S. Entyvio Grew Just 0.7% in FY2025, and ¥5,968 Sits 29% Above the ¥4,625 Conservative DCF Takeda is a Tokyo-listed global biopharma spanning GI, plasma-derived therapies, rare disease, oncology, neuroscience and vaccines, whose FY2025 revenue of ¥4.51tn still leans on Entyvio (about 21% of revenue), immunoglobulin and the post-Shire portfolio while ORZEYFUL, MIMRYLO and zasocitinib are meant to restore growth. FY2025 Core operating profit reached ¥1,172.5bn at a 26.0% margin, but a ¥402.5bn AMITIZA antitrust provision cut reported operating profit to ¥6.2bn; in Q1 FY2026 revenue rose 10.2% in yen while Core revenue fell 0.5% at CER and adjusted free cash flow dropped 63.9%, with leverage at 2.6x against a 2x target. Rating Hold: at ¥5,968 the stock trades at 12.6 times FY2026 Core EPS guidance and sits inside the ¥5,500–7,400 acceptable-hold band, but about 29% above the ¥4,625 conservative DCF, leaving no margin of safety; the ideal buy price is ¥3,500–3,700. Takeda Pharmaceutical Company Limited4502 · TSEPharmaceuticalsSep 24, 2026